Partners with biopharmaceutical companies to develop and license antibody-based cancer drug candidates for patients; also develops its own cancer treatments and provides drug manufacturing services.
10-K for FY2025, filed Mar 9, 2026
Biopharmaceutical partners pay upfront license fees, option and milestone payments, and royalties when licensed products sell; they also pay for research and manufacturing work as it is performed.
10-K for FY2025, filed Mar 9, 2026The Company enters into licensing agreements that are within the scope of ASC 606, under which it may license rights to research, develop…View ↗
Research, Development and/or Manufacturing Services. The promises under the Company’s agreements may include research and development or…View ↗
Customer Options. If an arrangement contains customer options, the Company evaluates whether the options are material rights because they…View ↗
Milestone Payments. At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the…View ↗
Royalties. For arrangements that include sales-based royalties which are the result of a customer-vendor relationship and for which the…View ↗
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗$149.5M
10-K for FY2025, filed Mar 9, 2026
$149.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaborative and other agreements
|
58%
FY2022: 79%
|
Collaborative and other agreements, FY2025
$87.2M Sources
|
|
|
Contract manufacturing
Recurring
10-K for FY2025, filed Mar 9, 2026 |
35%
FY2022: 9.2%
|
Contract manufacturing, FY2025
$52.6M Sources
|
Recurring |
|
Product sales, net
|
0.0%
FY2022: 11%
|
Product sales, net, FY2025
$0 Sources
|
|
|
Royalty revenue
Licensed
|
6.5% |
Royalty revenue, FY2025
$9.7M Sources
|
Licensed |
Biopharmaceutical collaborators license product candidates and work with MacroGenics on development; collaborators and other third parties use its contract development and manufacturing services.
10-K for FY2025, filed Mar 9, 2026
No. It lost $74.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$20.1MView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
8-K, filed Jul 7, 2026
Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets…View ↗
Growing. Revenue grew 93% in 4 years, from $77.4M in FY2021 to $149.5M in FY2025, about 18% a year.
MARGENZA commercialization
The earlier report described MacroGenics marketing MARGENZA with a partner; the latest says it sold global rights to TerSera and may receive sales milestone payments.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 9, 2026In March 2021, we and our commercialization partner commenced U.S. marketing of MARGENZA (margetuximab-cmkb), a human epidermal growth…View ↗
In October 2024, we announced that we had entered into an agreement in which TerSera Therapeutics LLC (TerSera), a privately-held…View ↗
Competes with Akeso, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals, Abbvie, BeOne Medicines, BioNTech, Duality Biotherapeutics, Genmab, GSK, Hansoh Pharmaceutical, Innovent Biologics, MediLink Therapeutics, Merck &, Pfizer, Amgen, F. Hoffmann-La Roche, Genentech, Janux Therapeutics, Johnson & Johnson Services, and Regeneron Pharmaceuticals
10-K for FY2025, filed Mar 9, 2026In particular, we are developing a PD-1 and CTLA-4 directed DART molecule, which if successful, will likely face significant competition…View ↗
Loading...